Editorial Comment to “Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab”
The treatment landscape for metastatic renal cell carcinoma (mRCC) has changed significantly with the advent of combination therapies based on immune checkpoint inhibitors (ICIs). Currently, nivolumab plus ipilimumab (NIVO+IPI) and ICI plus tyrosine kinase inhibitor (IO–TKI) combination therapies are widely used as fir...